A 6-month course of valaciclovir therapy has been shown to mediate a 28% reduction the proportion of CD4+CD28- T cells in patients undergoing immunosuppressive therapy for vasculitis and was associated with enhanced immune response to pneumococcal vaccination [40]. The gene discussed is CD28; the disease is vasculitis.